Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma

Annals of Oncology

Volumn 14, Issue SUPPL. 1, 2003, Pages

  Zelenetz, A D ^a   Hamlin, P ^a   Kewalramani, T ^a   Yahalom, J ^a   Nimer, S ^a   Moskowitz, C H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; MESNA; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; MALE; META ANALYSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0038511354     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg702     Document Type: Article

References (25)

1. Fisher RI, Gaynor ER, Dahlberg S et al. A phase III comparison of CHOP versus m-BACOD versus ProMACE-CytaBOM versus MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994; 5: 91-95.
2. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
3. Philip T, Chauvin F, Armitage J et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77: 1587-1592.
4. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-122.
5. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169-1176.
6. Colwill R, Crump M, Couture F et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995; 13: 396-402.
7. Girouard C, Dufresne J, Imrie K et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997; 8: 675-680.
8. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-3785.
9. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
10. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
11. Nadler LM, Ritz J, Hardy R et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981; 67: 134-140.
12. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
13. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
14. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112-2135.
15. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-86.
16. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Azen SP, Roy S, Pike MC et al. A new procedure for the statistical evaluation of intrauterine contraception. Am J Obstet Gynecol 1977; 128: 329-335.
19. Kewalramani T, Zelenetz A, Bertino J et al. Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT). Orlando, Fl, USA: American Society of Hematology 2001.
20. Dreger P, Marquardt P, Haferlach T et al. Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993; 68: 950-957.
21. Magagnoli M, Sarina B, Balzarotti M et al. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 2001; 28: 923-927.
22. Mayer J, Vasova I, Koristek Z et al. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Eur J Haematol Suppl 2001; 64: 21-27.
23. 2 and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278-282.
24. Pavone V, Gaudio F, Guarini A et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285-290.
25. McLaughlin P, Velasquez WS, Redman JR et al. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst 1988; 80: 1408-1412.